UNSPSC 51432509: Oxprenoate

This classification denotes an antihypertensive agent with the molecular formula C25H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2JGY63UVRO, chemically known as 3-[(7R,8R,9S,10R,13S,14S,17R)-17-hydroxy-10,\13-dimethyl-3-oxo-7-propyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate but generally known as oxprenoate, which bears US NIH Compound Identifier 23677972.

UNSPSC 51432509 Oxprenoate is a Commodity code covering pharmaceutical products, specifically advanced life support and emergency medications being procured by state and local health and human services agencies. State and local governments buy injectable medications—epinephrine, labetalol, adenosine, diltiazem, and similar compounds—for emergency medical services, hospital formularies, and public health programs. Recent solicitations show fire rescue departments, state health commissions, and cooperative purchasing alliances sourcing these drugs through competitive bidding processes that emphasize firm pricing, product quality assurance (including expiration-date management and defect warranties), OSHA compliance documentation, and delivery timelines measured in days. The issuing bodies mix city purchasing departments (Tampa Fire Rescue), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP), with the latter representing a consolidation mechanism used by state and local facilities across multiple jurisdictions to achieve volume-based pricing leverage.

Recent activity concentrates in Florida and Texas, with multistate reach through cooperative purchasing frameworks. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, for advanced life support medications with a due date of April 8, 2026, and an estimated contract value of $40,000, requiring delivery within ten calendar days and supply through authorized wholesalers with nine-month minimum expiration dates. Texas HHS Commission posted an RFI (HHS0017013) in early April 2026 to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish multiple contracts for generic pharmaceuticals and OTC products, effective July 1, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and requiring manufacturing compliance with cGMP and Drug Supply Chain Security Act standards. MMCAP's cooperative approach pools demand across state and local member facilities in Minnesota, Oregon, and other participating jurisdictions, offering sustained volume opportunity for manufacturers meeting wholesaler certification and administrative fee requirements.